The company was last valued at $2.2B in August 2021. Here are the top-line bullets you need to know.
Reify Health, a provider of clinical trial management software, has raised $220M in a Series D. The round drew participation from Altimeter Capital, Coatue Management, and Dragoneer Investment Group, among others.
HOW’S THE COMPANY PERFORMING?
- Massachusetts-based Reify Health provides solutions designed to optimize clinical trials and make clinical trial research more widely accessible.
- Its StudyTeam platform (focused on patient recruitment and enrollment) is available in 100+ countries.
- Reify Health has catered to top pharma and healthcare firms and thousands of research clinics – some of its customers include AstraZeneca, Eli Lilly & Co, Merck & Co, Sanofi, and Amgen.
Source: Reify Health
WHY DOES THE MARKET MATTER?
- The global clinical trials market is expected to reach a value of $69.3B by 2028, growing at a CAGR of 5.7%, according to Grand View Research.
- The rising prevalence of chronic diseases, the growing demand for personalized medication, and the globalization of clinical trials are some of the key factors contributing to market growth.
- The increasing application of AI to clinical trial solutions is also driving market growth. This tech has proven to help better identify patients for clinical trials, speed up clinical trials, and bring drugs to market faster.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
